CRO Data Integrity Concerns Have Pharma Companies Scrambling to Repeat Bioequivalence Studies
BioSpace
SEPTEMBER 28, 2021
The announcement came following independent FDA analyses of inspections conducted at the two CROs in November 2019.
94 
The drug industry continues to dare regulation
World of DTC Marketing
FEBRUARY 21, 2022
didn’t just offer to pay for the drug’s development cost so that the price could be set very low, but it’s about investors who penalized the company stock when they learned that COVID might be on the decline. At this point, one must wonder why the U.S. About those copay cards. spending annually.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
In the News: October Regulatory and Development Updates
Camargo
NOVEMBER 11, 2020
In November 2017, Foundation Medicine received approval for FoundationOne CDx , a genomic profiling test for solid state tumors, which paved the way for partnerships with pharma companies’ therapeutics. In 2019, Foundation Medicine and Bayer Healthcare Pharmaceuticals, Inc. for patients with NTRK fusion cancer across all solid tumors.
Pioneering access to complex generic productsÂ
Drug Discovery World
AUGUST 22, 2023
Originator pharma companies are developing ever more complex products, which are transforming the medical landscape, but their cost places an increasing burden on healthcare budgets worldwide. Opportunities Originator pharma companies are developing more and more complex products these days.
Let's personalize your content